Leukemia

Moxetumomab pasudotox-tdfk, approved as a treatment for relapsed/refractory hairy cell leukemia in 2018, will be withdrawn from the United States market in July 2023.

The FDA gave the dual epigenetic modulator JBI-802 an orphan drug designation to treat small cell lung cancer and acute myeloid leukemia.

The Japanese approval of acalabrutinib for the treatment of patients with treatment-naïve chronic lymphocytic leukemia was supported by data from the phase 3 ELEVATE-TN trial.

Data presented at this year’s American Society of Hematology Annual Meeting spotlight promising novel treatment options for acute myeloid leukemia, according to an expert from The University of Texas MD Anderson Cancer Center.

Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.

Kendra Sweet, MD, examined how the data surrounding asciminib in chronic myeloid leukemia will affect the standard of care treatment options.

Kendra Sweet, MD, discussed results of the the phase 2 OPTIC trial, which investigated ponatinib in a group of patients with resistant, chronic phase chronic myeloid leukemia.

Following the 2022 ASH Annual Meeting and Exposition, Nakhle Saba, MD; Lindsey Roeker, MD; Javier Pinilla, MD, PhD; and Catherine C. Coombs, MD, participated in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics ranged from most exciting data in chronic lymphocytic leukemia and lymphoma, as well as what research needs more follow-up.

Susan O’Brien, MD, provides a brief overview of chronic lymphocytic leukemia (CLL), and Seema Ali Bhat, MD, explains the mechanism of BTK inhibitors.

The original guidance was published as a draft 2 years ago, detailing the FDA's thoughts on the development of agents for the treatment of acute myeloid leukemia.

Harry P. Erba, MD, PhD, highlights key data on ziftomenib in patients with relapsed/refractory acute myeloid leukemia and its potential as part of a combination regimen.

Patients with IDH1-mutant relapsed/refractory acute myeloid leukemia achieved a notable complete response rate following treatment with olutasidenib.

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma achieved promising early responses following treatment with BCB-11417 with or without zanubrutinib.

Those with chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and those with CML whose tumors have a T315I mutation, were found to have improved efficacy when olverembatinib was given.

Blinatumomab plus consolidation chemotherapy produced a 58% reduction in the risk of death vs consolidation chemotherapy alone in patients with MRD-negative B-cell acute lymphoblastic leukemia.

Results from the phase 3 ALPINE trial found improved progression-free survival and overall response rate when Zanubrutinib was given to patients with chronic lymphocytic leukemia or small lymphatic leukemia vs ibrutinib.

The average time to next treatment among patients with chronic lymphocytic leukemia occurred faster in those treated with acalabrutinib vs ibrutinib.

Magrolimab in combination with azacitidine and venetoclax was well tolerated and yielded promising responses among patients with high-risk acute myeloid leukemia regardless of TP53 mutation status.

Ziftomenib monotherapy showed pronounced antileukemic activity and a tolerable toxicity profile in pretreated patients with relapsed/refractory acute myeloid leukemia.

Patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia, chronic phase, or acute phase who are resistant to tyrosine kinase inhibitors were found to show a clinical benefit with olvermbatinib.

A potential efficacy benefit has been observed with lintuzumab-Ac225 plus salvage therapy for patients with relapsed/refractory acute myeloid leukemia.

The phase 3 ASAP trial found the use of watchful waiting followed by sequential conditioning prior to allogeneic hematopoietic cell transplantation found a similar survival benefit in patients with relapsed/refractory acute myeloid leukemia.

Revumenib, which was given a breakthrough therapy designation by the FDA, may be beneficial in the management of relapsed or refractory KMT2A-rearranged acute leukemia based on data from the phase 1 AUGMENT-101 trial.

The FDA’s approval of oral olutasidenib provides adults with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation a new treatment option.

The use of hypomethylating drugs such as azacitidine and decitabine improved outcomes for patients of advanced age with acute myeloid leukemia, according to findings from a recent retrospective study of real-world data.